Pharmacotherapeutic targets in Alzheimer's disease
Yif'at Biran, Colin L Masters, Kevin J Barnham, Ashley I Bush, Paul A Adlard
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE | WILEY | Published : 2009
Alzheimer's disease (AD) is a progressive neurodegenerative disorder which is characterized by an increasing impairment in normal memory and cognitive processes that significantly diminishes a person's daily functioning. Despite decades of research and advances in our understanding of disease aetiology and pathogenesis, there are still no effective disease-modifying drugs available for the treatment of AD. However, numerous compounds are currently undergoing pre-clinical and clinical evaluations. These candidate pharma-cotherapeutics are aimed at various aspects of the disease, such as the microtubule-associated tau-protein, the amyloid-beta(Abeta) peptide and metal ion dyshomeostasis--all o..View full abstract
The authors would like to acknowledge Dr. Robert Cherny for discussing the ideas presented. Y. B. is supported by the Commonwealth Scientific and Industrial Research Organization (CSIRO) Preventative-Health Flagship. P. A. A., C. L. M., K.J.B. and A. I. B. are consultants to Prana Biotechnology. We gratefully acknowledge the support of the National Health and Medical Research Council of Australia, Australian Research Council and the Alzheimer's Association (USA).